BioStock: Biosergen advances BSG005 antifungal drug candidate trial

Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections. The company has enrolled the first cohort in their phase Ib Proof-of-Concept trial, with 5 out of a total of 15 patients included so far. Biosergen’s CEO, Tine Olesen, came to BioStock's studio to discuss this milestone,  the company’s financing and the next steps ahead.

See the interview with CEO Tine Olesen at biostock.se:

https://www.biostock.se/en/2024/10/biosergen-advances-bsg005-antifungal-drug-candidate-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/